ENLV News & Events

Enlivex announced the issuance of an Australian patent. The patent will provide Enlivex with added intellectual property protection in Australia through at least 2040 with claims covering methods of using Allocetra to treat subjects with osteoarthritis. With this issuance, the company has secured patent protection for Allocetra in osteoarthritis in an additional major jurisdiction, further strengthening its global intellectual property position as the Phase 2b clinical program for Allocetra advances. Enlivex recently reported the dosing of the first patient at a U.S. clinical site in the Phase 2b clinical trial of Allocetra for the treatment of patients with moderate-to-severe age-related symptomatic primary knee osteoarthritis. The Phase 2b follows Enlivex's previous announcement regarding three-month and six-month topline data from the Phase 2b stage of ENX-CL-05-001, a multi-center, two-stage Phase I/II double-blind, randomized, placebo-controlled clinical trial that evaluated Allocetra in patients with moderate-to-severe knee OA.

Enlivex commented on the Rain Foundation's announcement of a $100M liquidity commitment to Rain's prediction markets protocol, which currently positions Rain as the third-largest prediction market protocol globally by Total Value Locked, alongside Polymarket and Kalshi. "We believe that Rain's positioning among the three largest prediction market platforms globally is a major step in Rain's quest to become a leading decentralized prediction market protocol, and a meaningful validation of our treasury strategy," said Shai Novik, executive chairman of Enlivex. "We further believe that the scale of capital deployment reflects strong conviction in the continued growth of Rain, and reinforces our confidence in the dual strategy we have built for Enlivex."

Enlivex announced the dosing of the first patient at a United States clinical site in the Phase 2b clinical trial of Allocetra for the treatment of patients with moderate-to-severe age-related symptomatic primary knee osteoarthritis.

Enlivex Therapeutics files to sell 23.33M ordinary shares for holders